Boule Diagnostics AB (BOUL)
Nasdaq Stockholm · Sweden · prices in SEK · close of 27 Oct 2026
Key indicators
| Last close | SEK 1.100 |
|---|---|
| 52-week range | 0.944 – 6.640 |
| Return, 1 month / 3 months | −53.2% / −70.9% |
| Return, 1 year / 3 years | −79.6% / −87.8% |
| Trend | Below its 200-day average |
| RSI (14) | 17 |
| Volatility (1 year) | 74.9% |
| Worst drawdown (1 year) | -83.0% |
| Average daily value traded | 0.17M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Boule Diagnostics AB is a Swedish medical diagnostics company that develops and manufactures instruments and reagents for blood cell analysis. Its systems perform complete blood counts and related tests, and are used by healthcare providers such as primary care clinics, small hospitals and laboratories, as well as veterinary practices. The company is based in Sweden and supplies customers in many countries through its own sales channels and distribution partners.
The shares are listed on the Nasdaq Stockholm in Sweden under the code BOUL, and the price on this page is in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Boule Diagnostics AB (BOUL) trades on the Nasdaq Stockholm in Sweden. It last closed at SEK 1.100 on 27 October 2026.
Its price-based Market X-Ray is 14 out of 100 (a weak price profile), ranking 856 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 79.6% and over the last three months it fell 70.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Stockholm
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 5 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -69.2% | ||
| From 52-week high | -83.0% | ||
| Momentum | 5 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -70.9% | ||
| 6-month return | -71.2% | ||
| 12-month return, skipping the last month | -56.3% | ||
| Stability (higher is calmer) | 18 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 74.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -83.0% | ||
| Liquidity | 36 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.17M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −45.5% |
|---|---|
| 1 month | −53.2% |
| 3 months | −70.9% |
| 6 months | −71.2% |
| 1 year | −79.6% |
| 3 years | −87.8% |
| 5 years | −96.9% |
Signals
| 50-day / 200-day average | 2.531 / 3.569 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.238 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 May 2022 | SEK 0.5500 |
| 7 May 2021 | SEK 0.5500 |
| 7 May 2019 | SEK 0.5500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Stockholm; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.